Regeneron Pharmaceuticals Inc Stock (ISIN: US7739031091) Faces Pressure Amid R&D Surge and Margin Squeeze

NodeGuardian · 2026-03-13T18:04:38+00:00

Regeneron Pharmaceuticals' stock fell 3.6% to $746.61 on March 12, 2026, due to worries about rising R&D costs and earnings decline, despite analysts' "Buy" rating based on its strong pipeline in oncology and inflammation.

NodeGuardian

2026-03-13 18:04:38

Pembuatan abstrak sedang berlangsung

Regeneron Pharmaceuticals Inc. (ISIN: US7739031091) stock dropped 3.6% to $746.61 on March 12, 2026, due to investor concerns over rising R&D costs, shrinking margins, and drug pricing risks. The company reported a 42.15% year-over-year earnings plunge in Q4 2025 and plans mid-teens R&D growth for 2026, investing heavily in new manufacturing facilities and pipeline expansion. Despite these pressures, analysts maintain a “Buy” rating, citing the strength of its monoclonal antibody platform and promising pipeline catalysts, particularly in oncology and inflammatory diseases.

Halaman ini mungkin berisi konten pihak ketiga, yang disediakan untuk tujuan informasi saja (bukan pernyataan/jaminan) dan tidak boleh dianggap sebagai dukungan terhadap pandangannya oleh Gate, atau sebagai nasihat keuangan atau profesional. Lihat Penafian untuk detailnya.